Entrada Therapeutics (TRDA) Capital Expenditures (2020 - 2025)
Entrada Therapeutics' (TRDA) quarterly Capital Expenditures came in at $121000.0 in Q4 2025, down 97.67% year-on-year from $5.2 million in Q4 2024, and up 436.11% quarter-over-quarter from -$36000.0 in Q3 2025.
Entrada Therapeutics (TRDA) Capital Expenditures (2020 - 2025) Analysis & Trends
Entrada Therapeutics' Capital Expenditures history runs 6 years deep, the most recent figure standing at $121000.0 for Q4 2025.
- On a quarterly basis, Capital Expenditures fell 97.67% year-over-year to $121000.0 in Q4 2025; TTM through Mar 2026 was -$108000.0, a 103.43% decrease from a year earlier, with the FY2024 full-year figure at $3.2 million, down 43.75% from the prior year.
- Capital Expenditures grew to $121000.0 in Q4 2025 per TRDA's latest filing, from -$36000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $8.6 million in Q1 2023 and bottomed at -$7.7 million in Q2 2023.
- The 5-year median for Capital Expenditures is $256000.0 (2022), against an average of $672000.0.
- Biggest YoY gain for Capital Expenditures was 2107.93% in 2023; the steepest drop was 1895.88% in 2023.
- Year by year, Capital Expenditures stood at $2.7 million in 2021, then tumbled by 178.7% to -$2.1 million in 2022, then surged by 146.68% to $976000.0 in 2023, then jumped by 432.99% to $5.2 million in 2024, then plunged by 97.67% to $121000.0 in 2025.
- Per Business Quant, the three latest TRDA Capital Expenditures figures stand at $121000.0 (Q4 2025), -$36000.0 (Q3 2025), and -$193000.0 (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Entrada Therapeutics | 253.11 Mn | 253.11 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 121,000.00 |
| Dec 31, 2025 | 121,000.00 |
| Sep 30, 2025 | -36,000.00 |
| Sep 30, 2025 | -36,000.00 |
| Jun 30, 2025 | -193,000.00 |
| Jun 30, 2025 | -193,000.00 |
| Mar 31, 2025 | 108,000.00 |
| Mar 31, 2025 | 108,000.00 |
| Dec 31, 2024 | 5.20 Mn |
| Dec 31, 2024 | 5.20 Mn |
| Sep 30, 2024 | -3.93 Mn |
| Sep 30, 2024 | -3.93 Mn |
| Jun 30, 2024 | 1.77 Mn |
| Jun 30, 2024 | 1.77 Mn |
| Mar 31, 2024 | 115,000.00 |
| Mar 31, 2024 | 115,000.00 |
| Dec 31, 2023 | 976,000.00 |
| Dec 31, 2023 | 976,000.00 |
| Sep 30, 2023 | 3.75 Mn |
| Sep 30, 2023 | 3.75 Mn |